Difficulties in echocardiographic monitoring of trastuzumab therapy in breast cancer patients: Case report and review of recommendations;Trudności w monitorowaniu echokardiograficznym leczenia trastuzumabem chorych na raka piersi - Opis przypadku i przegla̧d zaleceń

Kardiologia Polska

Volumn 66, Issue 8, 2008, Pages 895-898

  Duchnowska, Renata ^a   Szmit, Sebastian ^a,b,c   Szczylik, Cezary ^a   Opolski, Grzegorz ^b  

^a MILITARY INSTITUTE OF MEDICINE   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

^c WARSZAWSKI UNIWERSYTET MEDYCZNY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

TRASTUZUMAB;

BREAST CANCER; CANCER CHEMOTHERAPY; CASE REPORT; ECHOCARDIOGRAPHY; HUMAN; PATIENT MONITORING; REVIEW;

EID: 54049098331     PISSN: 00229032     EISSN: 00229032     Source Type: Journal    
DOI: None     Document Type: Review

References (11)

1. Jassem J, et al. Rak piersi. In: Krzakowski M (ed.). Zalecenia postȩpowania diagnostyczno-terapeutycznego w nowotworach złośliwych. Via Medica, Gdańsk 2007: 208-9.
2. Douglas PS, Khandheria B, Stainback RF, et al. ACCF/ASE/ACEP/ASNC/SCAI/ SCCT/SCMR 2007 appropriateness criteria for transthoracic and transesophageal echocardiography: a report of the American College of Cardiology Foundation Quality Strategic Directions Committee Appropriateness Criteria Working Group, American Society of Echocardiography, American College of Emergency Physicians, American Society of Nuclear Cardiology, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and the Society for Cardiovascular Magnetic Resonance endorsed by the American College of Chest Physicians and the Society of Critical Care Medicine. J Am Coll Cardiol 2007; 50: 187-204.
3. Cheitlin MD, Armstrong WF, Aurigemma GP, et al. ACC/AHA/ ASE 2003 guideline update for the clinical application of echocardiography: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). J Am Coll Cardiol 2003; 42: 954-70.
4. Rastogi P, Jeong J, Geyer CE, et al. Five year update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/ cyclophosphamide (AC).paclitaxel (T) vs. AC.T with trastuzumab (H). J. Clin Oncol 2007; 25: 6s.
5. Tan-Chiu E, Yothers G, Ramond E, et al. Assesment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab as adjuvant therapy in node positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005; 23: 7811-9.
6. Perez E, Suman VJ, Davidson NE, et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 2008; 26: 1231-8.
7. Suter TM, Procter M, van Veldhuisen DJ, et al. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 2007; 25: 3859-65.
8. Telli ML, Hunt SA, Carlson RW, et al. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol 2007; 25: 3525-33.
9. Ewer MS, Vooletich MT, Durand J, et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 2005; 23: 7820-6.
10. Kasprzak JD, Hoffman P, Płońska E, et al. Echokardiografia w praktyce klinicznej - Standardy Sekcji Echokardiografii Polskiego Towarzystwa Kardiologicznego 2007. Kardiol Pol 2007; 65: 1142-62.
11. Galderisi M, Marra F, Esposito R, et al. Cancer therapy and cardiotoxicity: the need of serial Doppler echocardiography. Cardiovasc Ultrasound 2007, 5: 4.